Nitric oxide and blood pressure: Effects of nitric oxide deficiency

Current Opinion in Nephrology and Hypertension

Volumn 5, Issue 1, 1996, Pages 80-88

  Baylis, Christine ^a,c   Vallance, Patrick ^b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Robert C Byrd HSC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE;

BLOOD PRESSURE REGULATION; DRUG DEFICIENCY; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; BLOOD PRESSURE; DIET; KIDNEY; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; BLOOD PRESSURE; DIET; HUMANS; HYPERTENSION; KIDNEY; NITRIC OXIDE;

EID: 0029661490     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199601000-00014     Document Type: Article

References (109)

1. Raij L, Baylis C: Nitric oxide and the glomerulus. Editorial review. Kidney Int 1995, 48:20-32. A current, extensive review of physiologic and pathophysiologic glomerular actions of NO.
2. Ito S: Nitric oxide in the kidney. Curr Opin Nephrol Hypertens 1995, 4:23-30.
3. Baylis C, Qiu C: Importance of nitric oxide (NO) in control of renal hemodynamics. Kidney Int (in press).
4. Wang Y, Marsden PA: Nitric oxide syntheses: biochemical and molecular regulation. Curr Opin Nephrol Hypertens 1995, 4:12-22.
5. Bachmann S, Mundel P: NO in the kidney: synthesis, localization and function. Am J Kidney Dis 1994, 24:112-129.
6. Ujiie K, Yuen J, Danzinger R, Star RA: Localization and regulation of endothelial NO synthase mRNA expression in rat kidney. Am J Physiol 1994, 267:F296-F302.
7. Baylis C, Mitruka B, Deng A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992, 90:278-281.
8. Ribeiro MO, Antunes E, DeNucci G, Lovisolo SM, Zatz R: Chronic inhibition of nitric oxide synthesis: a new model of arterial hypertension. Hypertension 1992, 20:298-303.
9. 2 does not contribute to impaired endothelium-dependent relaxation. Arterioscler Thromb 1994, 14:746-752.
10. Cayatte AJ, Palacino JJ, Horten K, Cohen RA: Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994, 14:753-759.
11. Deng A, Samsell L, Baylis C: Glomerular hemodynamic effects of fenoldapam (F) in S/6th renal ablation (ABL) and chronic nitric oxide blockade (NOB) induced systemic and glomerular hypertension [Abstract]. J Am Soc Nephrol 1993, 4:767A.
12. Brenner BM: Nephron adaptation to renal injury or ablation. Am J Physiol 1985, 249:F324-F337.
13. Fujihara CK, DeNucci G, Zatz R: Chronic nitric oxide synthase inhibition aggravates glomerular injury in rats with subtotal nephrectomy. J Am Soc Nephrol 1995, 5:1498-1507.
14. Garg UC, Hassid A: Inhibition of rat mesangial cell mitogenesis by nitric oxide-generating vasodilators. Am J Physiol 1989, 257:F60-F66.
15. Kolpakov V, Gordon D, Kulik TJ: Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells. Circ Res 1995, 76:305-309.
16. Radner W, Hoger H, Lubec B, Slazer H, Lubec G: L-arginine reduces kidney collagen accumulation and N-ε-(carboxymethyl) lysine in the aging NMRI-mouse. J Gerontol 1994, 49:M44-M46.
17. Grond J, Weening JJ: Mesangial cell injury, glomerulosclerosis, and therapeutic intervention. Nutr Pharmacol Strat Chronic Renal Fail 1990, 81:229-239.
18. Tagami M, Ikeda K, Nara Y, Fujino H, Kubota A, Numano F, Yamori Y: Detailed examination of vascular lesions triggered by an inhibitor of endothelium-derived relaxing factor. Lab Invest 1995, 72:174-182.
19. x) excretions [Abstract]. J Am Soc Nephrol 1994, 5:549.
20. Committee on Nitrate and Alternative Curing Agents in Food, National Academy of Sciences: The health effects of nitrate, nitrite and N-nitroso compounds. Washington, DC: National Academic Press; 1981.
21. Leone AM, Francis PL, Rhodes P, Moncada S: A rapid and simple method for the measurement of nitrite and nitrate in plasma by high performance capillary electrophoresis. Biochem Biophys Res Commun 1994, 200:951-957.
22. Baylis C, Davison J: The normal renal physiological changes which occur during pregnancy. In The Oxford Textbook of Clinical Nephrology 2nd Edition. Edited by Cameron JS, Davison AM, Grunfeld JP, Kerr DNS, Ritz E. Oxford: Oxford University Press; (in press).
23. NOXV) do not predict renal vascular NO production. Kidney Int 1995, 48:1272-1277.
24. Arnal J-F, Warin L, Michel J-B: Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic Inhibition of nitric oxide synthase. J Clin Invest 1992, 90:647-652.
25. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA: Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994, 368:850-853. This study defines the mechanism by which NO causes hyperpolarization of vascular smooth muscle.
26. Baylis C, Harton P, Engels K: Endothelial derived relaxing factor (EDRF) controls renal hemodynamics in the normal rat kidney. J Am Soc Nephrol 1990, 1:875-881.
27. Hu L, Manning RD Jr, Brands MW: Long-term cardiovascular role of nitric oxide in conscious rats. Hypertension 1994, 23:185-194.
28. Dananberg J, Sider R, Grekin RJ: Sustained hypertension induced by orally administered nitro-L-arginine. Hypertension 1993, 21:359-363.
29. Qiu C, Engels K, Samsell L, Baylis C: Renal effects of amino acid infusion in hypertension induced by chronic nitric oxide blockade. Hypertension 1995, 25:61-66.
30. Morton JJ, Beattie EC, Speirs A, Gulliver F: Persistent hypertension following inhibition of nitric oxide formation in the young Wistar rat: role of renin and vascular hypertrophy. J Hypertens 1993, 11:1083-1088.
31. Li Jin-Sheng, Schiffrin EL: Resistance artery structure and neuroeffector mechanisms in hypertension induced by nitric oxide synthase. Am J Hypertens 1994, 7:996-1004.
32. Delacretaz E, Hayoz D, Osterheld MC, Genton CY, Brunner HR, Waeber B: Long-term nitric oxide synthase inhibition and distensibility of carotid artery in intact rats. Hypertension 1994, 23:967-970.
33. Bank N, Aynedjian HS, Khan GA: Mechanism of vasoconstriction induced by chronic inhibition of nitric oxide in rats. Hypertension 1994, 24:332-328.
34. 1-adrenergic tone in chronic nitric oxide blockade-induced hypertension in conscious rats. Am J Physiol 1994, 266:R1470-R1476.
35. Cunha RS, Cabral AM, Vasquez EC: Evidence that the autonomic nervous system plays a major role in the L-NAME-induced hypertension in conscious rats. Am J Hypertens 1993, 6:806-809.
36. Traystman RJ, Moore LE, Helfaer MA, Davis S, Banasiak K, Williams M, Hum PD: Nitro-L-arginine analogues. Dose and time related nitric oxide synthase inhibition in brain. Stroke 1995, 26:864-869.
37. Matsuoka H, Nishida H, Nomura G, VanVliet BN, Toshima H: Hypertension induced by nitric oxide synthesis inhibition is renal nerve dependent Hypertension 1994, 23:971-975.
38. G-nitro-L-arginine methyl ester treatment in conscious rats. Hypertension 1994, 23:982-986.
39. ••].
40. ••] represent the most extensive evaluation of the complex interactions between NO and renin release and help to explain earlier conflicts in the literature.
41. Beierwaltes WH: Selective neuronal nitric oxide synthase inhibition blocks furosemide-stimulated renin secretion in vivo. Am J Physiol 1995, 269:F134-F139.
42. Pollock DM, Polakowski JS, Divish BJ, Opgenorth TJ: Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension 1993, 21:660-666.
43. Jover B, Herizi A, Ventre F, Dupont M, Mimran A: Sodium and angiotensin in hypertension induced by long-term NO blockade. Hypertension 1993, 21:944-948.
44. Lahera V, Salazar J, Salom MG, Romero JC: Deficient production of nitric oxide induces volume-dependent hypertension. J Hypertens 1992, 10:8173-5177.
45. Fujihara CK, Michellazzo SM, DeNucci G, Zatz R: Sodium excess aggravates hypertension and renal parenchymal injury in rats with chronic NO inhibition. Am J Physiol 1994, 266:F697-F705.
46. G-monomethyl-L-arginine and nitroarginine potentiate pressor responsiveness of vasoconstrictors in conscious rats. Am J Physiol 1992, 262:R1137-R1144.
47. Qui C, Engels K, Baylis C: Endothelin modulates the pressor actions of acute systemic nitric oxide blockade. J Am Soc Nephrol 1995, 6:1476-1481.
48. Fujihara CK, Michelazzo SM, Zatz R: Long term endothelin blockade does not prevent the functional and morphologic consequences of chronic nitric oxide Inhibition [Abstract]. J Am Soc Nephrol 1994, 5:578.
49. Stoos BA, Garcia NH, Garvin JF: Nitric oxide inhibits sodium reabsorption in the isolated perfused cortical collecting duct. J Am Soc Nephrol 1995, 6:89-94. This study reports that NO directly inhibits sodium transport in the isolated perfused collecting duct.
50. McKee M, Scavone C, Nathanson JA: Nitric oxide, cGMP, and hormone regulation of active sodium transport. Proc Natl Acad Sci USA 1994, 91:12056-12060.
51. Tolins JP, Shultz PJ: Endogenous nitric oxide synthesis determines sensitivity to the pressor effect of salt. Kidney Int 1994, 46:230-236. This study demonstrates that the normal, normotensive response to increased dietary salt intake involves a stimulus to NO production.
52. Deng X, Welch WJ, Wilcox CS: Renal vasoconstriction during inhibition of NO synthase: effects of dietary salt. Kidney Int 1994, 46:639-646.
53. Chen PY, Sanders PW: L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest 1991, 88:1559-1567.
54. Chen PY, St John PL, Kirk KA, Abrahamson DR, Sanders PW: Hypertensive nephrosclerosis in the Dahl-Rapp rat. Initial sites of injury and effect of dietary L-arginine supplementation. Lab Invest 1993, 68:174-184.
55. Chen PY, Sanders PW: Role of NO synthesis in salt sensitive hypertension in Dahl/Rapp rats. Hypertension 1993, 22:812-818.
56. Patel AR, Granger JP, Kirchner KA: L-arginine improves transmission of perfusion pressure to the renal interstitium in Dahl salt-sensitive rats. Am J Physiol 1994, 266:R1730-R1735.
57. Kirchner KA, Crosby BA, Patel AR, Granger JP: Segmental chloride transport in the Dahl-S rat kidney during L-arginine administration. J Am Soc Nephrol 1995, 5:1567-1572.
58. Mattson DL, Lu S, Nakanishi K, Papanek PE, Cowley AW Jr: Effect of chronic renal medullary nitric oxide inhibition on blood pressure. Am J Physiol 1994, 266:H1918-H1926.
59. Johnson RA, Freeman RH: Pressure natriuresis in rats during blockade of the L-arginine/nitric oxide pathway. Hypertension 1992, 19:333-338.
60. Fernandez-Rivas A, Garcia-Estan J, Vargas F: Effects of chronic increase salt intake in nitric oxide synthesis inhibition-induced hypertension. J Hypertens 1995, 13:123-128.
61. Walder CE, Thiemermann C, Vane JR: The involvement of endothelium-derived relaxing factor in the regulation of renal cortical blood flow in the rat. Br J Pharmacol 1991, 102:967-973.
62. Slangen B, Weaver C, Baylis C: Renal effects of low dose NO Inhibition in the rat [Abstract]. J Am Soc Nephrol 1993, 4:569A.
63. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC: Hypertension in mice lacking the gene encoding for endothelial nitric oxide synthase. Nature 1995, 377:239-241. This paper confirms the importance of NO in blood pressure regulation by developing knockout mice lacking eNOS.
64. Mohaupt MG, Elzie JI, Ahn Ky, Clapp WL, Wilcox CS, Kone BC: Differential expression and induction of mRNAs encoding two inducible nitric oxide syntheses in rat kidney. Kidney Int 1994, 46:653-665.
65. Deng AY, Rapp JP: Locus for the inducible, but not a constitutive, nitric oxide synthase cosegregates with blood pressure in the Dahl salt-sensitive rat. J Clin Invest 1995, 95:2170-2177.
66. Qiu C, Baylis C: Chronic inhibition of inducible nitric oxide synthase (INOS) has no effect on blood pressure (BP) or renal hemodynamics in the normal rat [Abstract]. J Am Soc Nephrol 1994, 5:589.
67. Vallance P, Collier J, Moncada S: Effect of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989, II:997-1000.
68. Calver A, Collier J, Vallance P: Nitric oxide and cardiovascular control. Exp Physiol 1993, 98:303-326.
69. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO: Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest 1995, 95:1747-1755. A study of basal and stimulated NO in human large and small coronary vessels.
70. Haynes WG, Noon JP, Walker BR, Webb DJ: Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens 1993, 11:1375-1380.
71. Stamler JS, Loh E, Roddy MA, Currie KE, Creager MA: Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994, 89:2035-2040.
72. Hansen J, Jacobson TN, Victor RG: Is nitric oxide involved in the tonic inhibition of central sympathetic outflow in humans? Hypertens 1994, 24:439-444.
73. Vallance P, Patton S, Bhagat K, MacAllister R, Radomski M, Moncada S, Malinski T: Direct measurement of nitric oxide in humans. Lancet 1995, 346:153-154. Direct demonstration of generation of NO from human endothelium in vivo.
74. Hayashi Fukuto JM, Ignarro LJ, Chaudhuri G: Basal release of nitric oxide from aortic rings Is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci USA 1992, 89:11259-11263.
75. Scherre U, Randin D, Vollenweider P, Vollenweider L, Nicod P: Nitric oxide release accounts for Insulin's vascular effects in humans. J Clin Invest 1994, 94:2511-2515. A study that might link insulin resistance to endothelial function.
76. Griffith TM, Edwards DH, Davies RL, Harrison TJ, Evans KT: EDRF coordinates the behaviour of vascular resistance vessels. Nature 1987, 329:442-445.
77. Joannide R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Luscher TF: Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995, 91:1314-1319. This paper justifies the use of flow-mediated dilatation of conduit vessels as a non-invasive means to study NO.
78. Calver A, Collier J, Green D, Vallance P: Effect of acute plasma volume expansion on peripheral arteriolar tone in healthy subjects. Clin Sci 1992, 83:541-547.
79. Williams DJ, Moosavi AH, Imms FJ: Nitric oxide contributes to local heat induced vasodilatation in man. J Physiol 1995, 483:126-127.
80. Dietz NM, Rivera JM, Eggener SE, Fix RT, Warner DO, Joyner MJ: Nitric oxide contributes to the rise in forearm blood flow during mental stress in humans. J Physiol 1994, 480:361-368.
81. Bode-Boger SM, Boger RH, Schroder EP, Frolich JC: Exercise increases systemic nitric oxide production in men. J Cardiovasc Risk 1994, 1:173-178.
82. Baylis C: Nitric oxide in normal and preeclamptic pregnancy. In Nitric oxide and the kidney: physiology and pathophysiology. Edited by Goligorsky MS. London: Chapman Hall (in press).
83. Williams DJ, Valance PJT, Spencer JAD, Imms FJ: NO mediated vasodilatation in human pregnancy [Abstract]. Endothelium 1995, 3:S83.
84. Rosselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK: Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol and norethisterone acetate. A two-year follow-up study. Hypertension 1995, 25:848-853.
85. G monomethyl-L-arginlne in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens 1992, 10:1025-1031.
86. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA: Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993, 87:1468-1474.
87. Falloon BJ, Heagerty AM: In vitro perfusion studies of human resistance artery function in essential hypertension. Hypertension 1994 ,24:16-23.
88. Panza JA, Quyyumi AA, Brush JE, Epstein SE: Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Eng J Med 1990, 323:22-27.
89. Linder L, Kiowski W, Buhler FR, Luscher TF: Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 1990, 81:1762-1767.
90. Egashira K, Suzuki S, Hirooka Y, Kai H, Suigimachi M, Imaizumi T, Takeshita A: Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Hypertension 1995, 25:201-206. A study that translates some of the findings from forearm studies into the coronary vasculature of humans.
91. Celemajor DS, Sorenson KE, Bull C, Robinson J, Deanfield JE: Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994, 24:1468-1474.
92. Cadwgan TM, Benjamin N: Evidence for altered platelet nitric oxide synthesis in essential hypertension. J Hypertens 1993, 11:417-420.
93. Benjamin N, Copeland M, Smith LM: Reduced nitric oxide synthesis in essential hypertension [Abstract]. J Hypertens 1994, 12:1322.
94. Petrie JR, Shinichiro U, Webb DJ, Elliott HL, Connell JMC: Basal endothelial nitric oxide production and insulin sensitivity are positively related in man. J Hypertens (in press).
95. Cockcroft JR, Chowienczyk PJ, Benjamin N, Ritter JM: Preserved endothelium-dependent vasodilatation in patients with essential hypertension. N Eng J Med 1994, 330:1036-1040.
96. Taddei S, Virdis A, Mattei P, Salvetti A: Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993, 21:929-933.
97. Calver A, Collier J, Vallance P: Forearm blood flow responses to a nitric oxide synthase inhibitor in patients with treated essential hypertension. Cardiovasc Res 1994, 28:1720-1725.
98. G monomethyl-L-arginine in patients with essential hypertension. J Hypertens 1994, 12:1047-1052.
99. MacAllister R, Calver A, Riezebos J, Collier J, Vallance P: Relative potency and arterlovenous selectivity of nitrovasodilators on human blood vessels: an insight into the targeting of nitric oxide delivery. J Pharmacol Exp Ther 1995, 273:154-160. A paper that gives some insight into how novel antiplatelet and hypotensive NO-donors might be developed.
100. Billiar TR, Saavedra JE, Williams DL, Keefer LK: Towards design of a liver-specific nitric oxide donor. Endothelium 1995, 3:S13.
101. Drexler H, Zeiher AM, Meinzer K, Just H: Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991, 338:1546-1550.
102. MacAllister RJ, Calver AL, Collier J, Edwards CMB, Herreros B, Nussey SS, Vallance P: Vascular and hormonal responses to arginine: provision of substrate for nitric oxide or non-specific effect? Clin Sci 1995, 89:183-189.
103. Higashi Y, Oshima T, Ozono R, Watanabe M, Matsuura H, Kajiyama G: Effects of L-arginine Infusion on renal haemodynamics in patients with mild essential hypertension. Hypertension 1995, 25:898-902.
104. Hishikawa K, Nakaki T, Tsuda M, Esumi H, Ohshima H, Suzuki H, Saruta T, Kato R: Effect of systemic L-arginine administration on haemodynamlcs and nitric oxide release in man. Jpn Heart J 1992, 33:41-48.
105. Kanno K, Hirata Y, Emori T, Ohta K, Eguchi S, Imai T, Marumo F: L-arginine infusion induces hypotension and diuresis/natriuresis with concomitant increased urinary excretion of nitrite/nitrate and cyclic GMP in humans. Clin Exp Pharmacol Physiol 1992, 19:619-625.
106. Baudoulin SV, Bath P, Nartin JF, Du Bois R, Evans TW: L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamlcs in patients with elevated pulmonary vascular resistance. Br J Clin Pharmacol 1993, 36:45-49.
107. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339:572-575.
108. MacAllister R, Whitley G, Vallance P: Metabolism of methylarginines by human vasculature: implications for the regulation of nitric oxide synthesis. Br J Pharmacol 1994, 112:43-48. Identifies a novel biochemical pathway in human blood vessels that may regulate NO synthesis.
109. Higashi Y, Oshima T, Ono N, Hiraga H, Yoshimura M, Watanabe M, Matsuura H, Kambe M, Kajiyama G: Intravenous administration of L-arginine inhibits angiotensin-converting enzyme in humans. J Clin Endocrin Metab 1995, 80:2198-2202. A paper casting doubt on the specificity of the effects of the large doses of arginine that are often used in clinical investigation.